^
Association details:
| Biomarker: | ANG elevation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | bemcentinib (BGB324) (AXL inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Analysis of anti-leukemic activity, predictive biomarker candidates, immune activation and pharmakodynamics in R/R AML and MDS in response to treatment with bemcentinib (BGB324), a first-in class selective AXL inhibitor, in a phase II open-label, multi-centre study.
Published date:
05/16/2018
Excerpt:
N = 35 R/R AML or MDS (interm-2 and high-risk) pts received bemcentinib monotherapy...Levels of plasma soluble AXL and angiogenin and BM SLFN-11 expression correlated with pt benefit….Bemcentinib is well tolerated in MDS and AML pts and exhibits anti-leukemic activity through multiple mechanisms including immune modulation. Pt benefit (CRi/PR/SD > 4 mths) is predictable by measurement of plasma markers soluble AXL and angiogenin.
DOI:
10.1200/JCO.2018.36.15_suppl.7020
Trial ID:
